Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals Incorporated VRTX will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $501.00. The company’s shares ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...

Dell and HP are two of the biggest laptop brands for good reason. They both make plenty of great PCs, and whether you’re buying a laptop for school, work, gaming, everyday productivity, or all ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts Vertex Pharmaceuticals Inc. VRTX shares are trading higher Friday following two major developments that strengthen its position in both ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.